Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-escalation radiochemotherapy with concomitant and adjuvant temozolomide after high-dose methotrexate in primary central nervous system lymphoma
2007-003254-28Phase 2Terminated
- Sponsor
- Policlinico Gemelli
- Start
- Apr 2008
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of temozolomide in primary central nervous system lymphoma (PCNSL) and lymphoma, sponsored by Policlinico Gemelli. Primary endpoint: Maximum tolerated dose of concomitant temozolomide. Started Apr 2008; status: terminated.
02
Drugs
temozolomide
03
Conditions
primary central nervous system lymphoma (PCNSL)lymphoma
Beyond the preview
Go deeper on 2007-003254-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003254-28.